{"id":351,"date":"2025-09-12T14:09:54","date_gmt":"2025-09-12T12:09:54","guid":{"rendered":"https:\/\/bcamonitor.org\/?p=351"},"modified":"2026-09-22T13:05:54","modified_gmt":"2026-09-22T13:05:54","slug":"towards-new-clinical-practice-in-nmibc-monitoring","status":"publish","type":"post","link":"https:\/\/bcamonitor.org\/?p=351","title":{"rendered":"Towards new clinical practice in NMIBC monitoring?"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.16″ min_height=”392px” custom_margin=”||2px|||” custom_padding=”0px||0px|||” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row _builder_version=”4.16″ _module_preset=”default” custom_margin=”||8px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_text _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}” theme_builder_area=”post_content”]<\/p>\n

The DaBlaCa-15 trial paves the way for urinary biomarker integration<\/h1>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” min_height=”372px” custom_margin=”0px||||false|false” custom_padding=”0px||8px||false|false” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”Text” _builder_version=”4.16″ header_text_color=”#3b8dbf” header_6_font=”|300|||||||” background_size=”initial” background_position=”top_left” background_repeat=”repeat” min_height=”382.6px” custom_margin=”0px||||false|false” custom_padding=”0px||||false|false” global_colors_info=”{}” theme_builder_area=”post_content”]<\/p>\n

Reviewed by Joost Boormans<\/em><\/p>\n

 <\/p>\n

Non-muscle-invasive bladder cancer (NMIBC) demands diligent and often lifelong surveillance, primarily through frequent cystoscopies. While crucial for detecting recurrences, this intensive follow-up is invasive, can cause discomfort and anxiety for patients, and contributes significantly to healthcare costs. In addition, the use of labour and outpatient capacity, as well as the ecological footprint of lifelong surveillance are not to be neglected. The DaBlaCa-15 trial, a randomised controlled study, sought to challenge this paradigm by investigating a less invasive, yet equally effective approach with a urinary biomarker in the follow-up of NMIBC.<\/span><\/p>\n

 <\/p>\n

DaBlaCa-15 trial: Unpacking the key findings\u00a0<\/span><\/strong><\/span><\/p>\n

The DaBlaCa-15 trial, conducted across 4 urological centres in Denmark, randomised 392 patients with high-grade NMIBC [1]. The study was a non-inferiority trial of standard-of-care follow-up versus alternating the Xpert\u00ae Bladder Cancer Monitor (XBCM) urinary biomarker with cystoscopy could safely reduce the frequency of cystoscopies, while not jeopardizing oncological outcome in terms of high-grade recurrence-free survival. <\/span><\/p>\n

 <\/p>\n

\"\"<\/p>\n

 <\/p>\n

The trial’s primary outcome was the 2-year high-grade recurrence-free survival between the 2 study arms. The results were highly encouraging:<\/span><\/p>\n